Navigation Links
MedinCell to Explore Controlled-Release Drug Delivery Partnerships at the World Animal Health Congress
Date:12/2/2011

SAN DIEGO and MONTPELLIER, France, Dec. 2, 2011 /PRNewswire/ -- MedinCell, a leading developer of low-cost, controlled-release drug delivery technology, will be exploring partnerships for key companion and food animal markets with industry leaders at the Terrapinn World Animal Health Congress in Kansas City (December 6-8, 2011).

"MedinCell's biodegradable polymer technology offers exceptional control over the duration of drug release, thereby making small molecules—and even peptides—cost effective for the companion and food animal markets," said Dr. Alexandre Melin, Director of Animal Health for MedinCell. "Our platform's inherent flexibility enables us to design single-injection products that release drug molecules systemically over just a few days, or across multiple-months. With some APIs, we can achieve therapeutic plasma levels throughout an entire year," Dr. Melin (alexandre.melin@medincell.eu) continued.

Dr. Anh Nguyen, MedinCell Founder and CEO, explained, "MedinCell has experience formulating molecules for chemocastration, diabetes, pain control and parasitology. Our MedinGel™ technology brings a strong environmental benefit to animal health brands by reducing the required drug cargo, and therefore the amount of API cleared by the animals. This can also lead to a substantial reduction in product cost for animal health companies."

"MedinCell recognizes that the demand for protein production is increasing, and requires novel approaches to support the growing global population," commented Dr. Melin, who welcomes meeting requests at the World Animal Health Congress to discuss controlled-release strategies. "We look forward to designing novel products that improve product efficiency and animal treatment for the food animal industry," concluded Dr. Melin.

About MedinCell

MedinCell's patent-pending drug delivery technology, MedinGel, entraps drug molecules in a polymer matrix after injected. By limiting the initial drug burst, MedinCell can design formulations that extend release duration. With MedinGel, substantially less API cargo is required than for products designed for oral administration, which is a pivotal consideration for cost-sensitive markets such as animal health. MedinCell SA is headquartered in Montpellier, France, and recently launched formulation and R&D activities at its US subsidiary, MedinCell Corporation, in San Diego, California. Contact information for both facilities is available at www.medincell.com.

Information on the Terrapinn World Animal Health Congress is available online: http://www.terrapinn.com/2011/world-animal-health-congress/index.stm

 

 

CONTACT:  Chris Hoover, MedinCell Corporation, +1-858-216-4573, chris.hoover@medincell.com


'/>"/>
SOURCE MedinCell
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
4. 42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases
5. Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes
6. Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis
7. Webinar to Explore FDA Draft REMS Guidance and Its Implications for Lifecycle Management
8. New Manhattan Research Report Explores the Growing Consumer Demand for Online Health Video and How Pharma Marketers Can Leverage this Format
9. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
10. Advanced Life Sciences to Explore Strategic Alternatives to Maximize Shareholder Value
11. Retrospective Analysis Explores LYSTEDA®s Ability to Reduce Sleep Interruptions in Women With Cyclic Heavy Menstrual Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocytopenia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocytopenia Market and ... comprehensive insights into Thrombocytopenia pipeline products, ...
(Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
(Date:5/4/2016)... Israel , May 4, 2016 ... BiondVax,s CEO, Dr. Ron Babecoff , will be attending ... York City . On Thursday, May 5, ... a conference presented by Joseph Gunner & Co, ... The BiondVax presentation that Dr. Babecoff will be using is ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... ... Konur, CEO of Cardiovascular Institute of the South announced today that Dr. Robert ... live case of an Intravascular Ultrasound Guided Coronary Atherectomy. , This ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and ... to the impact our aging population has on communities and resources. Aging Life Care ... for and face age-related challenges. , Aging Life Care is a holistic, client-centered ...
(Date:5/5/2016)... Chicago, Illinois (PRWEB) , ... May 05, 2016 ... ... published its “deeming regulations” for electronic cigarettes, requiring e-cigarette manufacturers to submit ... as a “tobacco product,” apply to all vaping products that entered the market ...
(Date:5/5/2016)... ... ... from Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team Semper ... Mountain Bike Camp, hosted in conjunction with WTB and Cannondale in ... who’ll share pro tips with the injured veterans as they rip down some of the ...
(Date:5/5/2016)... , ... May 05, 2016 , ... LELO ... self-love. Every day, LELO fans reach out via email, social media and on the ... upcoming up: “Is the way I masturbate ‘normal’ or ‘correct’?” , While some methods ...
Breaking Medicine News(10 mins):